Antibody Responses to the BNT162b2 MRNA Vaccine in Individuals Previously Infected with SARS-CoV-2

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2021 Apr 2

PMID 33795870

Citations 366

Authors

Joseph E Ebinger

Justyna Fert-Bober

Ignat Printsev

Min Wu

Nancy Sun

John C Prostko

Edwin C Frias

James L Stewart

Jennifer E Van Eyk

Jonathan G Braun

Susan Cheng

Kimia Sobhani

Affiliations

Soon will be listed here.

Abstract

In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

Citing Articles

-specific TIGIT Treg are present in the blood of healthy subjects - a hurdle for vaccination?.

Clegg J, Mnich M, Carignano A, Cova G, Tavarini S, Sammicheli C Front Immunol. 2025; 15:1500696.

PMID: 39981298 PMC: 11840346. DOI: 10.3389/fimmu.2024.1500696.

An allelic atlas of immunoglobulin heavy chain variable regions reveals antibody binding epitope preference resilient to SARS-CoV-2 mutation escape.

Deng W, Niu X, He P, Yan Q, Liang H, Wang Y Front Immunol. 2025; 15():1471396.

PMID: 39840032 PMC: 11746035. DOI: 10.3389/fimmu.2024.1471396.

Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers.

Maher S, Assaly N, Aly D, Atta S, Fteah A, Badawi H Virol J. 2024; 21(1):277.

PMID: 39501293 PMC: 11539826. DOI: 10.1186/s12985-024-02546-0.

Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV.

Baldovin T, Leoni D, Geppini R, Miatton A, Amoruso I, Fonzo M Vaccines (Basel). 2024; 12(10).

PMID: 39460338 PMC: 11512344. DOI: 10.3390/vaccines12101172.

The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect.

Cin D, Soguksu P, Oren M, Ozgulnar N, Agacfidan A, Mese S Viruses. 2024; 16(9).

PMID: 39339885 PMC: 11437471. DOI: 10.3390/v16091409.